Cancer Letters
Volume 291, Issue 1 , Pages 76-82 , 1 May 2010

Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell

  • Yan-Hong Zhang

      Affiliations

    • Department of Oncology, Xuhui Central Hospital, Shanghai 200031, China
    • Corresponding Author InformationCorresponding authors.
    • ,
  • Qing Wu

      Affiliations

    • Department of Oncology, Shanghai First People’s Hospital, Shanghai Jiaotong University, Shanghai 200080, China
    • ,
  • Xiu-Ying Xiao

      Affiliations

    • Department of Oncology, Xuhui Central Hospital, Shanghai 200031, China
    • ,
  • Da-Wei Li

      Affiliations

    • Department of Oncology, Shanghai First People’s Hospital, Shanghai Jiaotong University, Shanghai 200080, China
    • ,
  • Xing-Peng Wang

      Affiliations

    • Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, China
    • Corresponding Author InformationCorresponding authors.

Received 6 September 2009 ,Revised 1 October 2009 ,Accepted 5 October 2009.

References 

  1. Nishiyama M. Chemotherapy for gastric cancer in Japan. Int. J. Clin. Oncol. 2008;13:191–192
  2. K. Nasseri, P.K. Mills, M. Allan, Cancer incidence in the Middle Eastern population of California 1988–2004, Asian Pac. J. Cancer Prev. 8 (2007) 405–411.
  3. McCracken M, Olsen M, Chen MS, Jemal A, Thun M, Cokkinides V, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J. Clin. 2007;57:190–205
  4. Zhou Y, Zhang Z, Zhang Z, Wu J, Ren D, Yan X, et al. A rising trend of gastric cardia cancer in Gansu province of China. Cancer Lett. 2008;269:18–25
  5. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008;266:99–115
  6. Wu A, Ji J. Adjuvant chemotherapy for gastric cancer or not: a dilemma?. J. Natl. Cancer Inst. 2008;100:376–377
  7. Chung YM, Park S, Park JK, Kim Y, Kang Y, Yoo YD. Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett. 2000;159:95–101
  8. Wilson TR, Longley DB, Johnston PG. Chemoresistance in solid tumours. Ann. Oncol. 2006;17(Suppl. 10):315–324
  9. Muggia F. Platinum compounds 30years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol. Oncol. 2009;112:275–281
  10. Yanglin P, Lina Z, Zhiguo L, Na L, Haifeng J, Guoyun Z, et al. KCNE2, a down-regulated gene identified by in silico analysis, suppressed proliferation of gastric cancer cells. Cancer Lett. 2007;246:129–138
  11. Chen L, Chen D, Gong M, Na M, Li L, Wu H, et al. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells. Cancer Lett. 2009;284:141–148
  12. Nakamura T, Kuwai T, Kitadai Y, Sasaki T, Fan D, Coombes KR, et al. Zonal heterogeneity for gene expression in human pancreatic carcinoma. Cancer Res. 2007;67:7597–7604
  13. Chu EC, Chai J, Ahluwalia A, Tarnawski AS. Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action?. Aliment Pharmacol. Ther. 2007;25:1443–1449
  14. Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin?. Cell Cycle. 2008;7:1353–1359
  15. Zisowsky J, Koegel S, Leyers S, Devarakonda K, Kassack MU, Osmak M, et al. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem. Pharmacol. 2007;73:298–307
  16. Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Oncol. Hematol. 2005;53:13–23
  17. Kitada N, Takara K, Minegaki T, Itoh C, Tsujimoto M, Sakaeda T, et al. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother. Pharmacol. 2008;62:577–584
  18. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006;66:8847–8857
  19. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin but not carboplatin and nedaplatin are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther. 2006;319:879–886
  20. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000;92:1295–1302
  21. Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst. 2000;92:1934–1940
  22. Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY, et al. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm. Res. 2005;22:1837–1853
  23. Chen C, Klaassen CD. Rat multidrug resistance protein 4 (Mrp4, Abcc4): molecular cloning, organ distribution, postnatal renal expression, and chemical inducibility. Biochem. Biophys. Res. Commun. 2004;317:46–53
  24. Janke D, Mehralivand S, Strand D, Godtel-Armbrust U, Habermeier A, Gradhand U, et al. 6-Mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Hum. Mutat. 2008;29:659–669
  25. Ho LL, Kench JG, Handelsman DJ, Scheffer GL, Stricker PD, Grygiel JG, et al. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate. 2008;68:1421–1429
  26. Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, Scheffer GL, et al. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol. Cancer Ther. 2005;4:547–553
  27. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther. 2007;320:229–235
  28. Wu CP, Calcagno AM, Hladky SB, Ambudkar SV, Barrand MA. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J. 2005;272:4725–4740

PII: S0304-3835(09)00624-7

doi: 10.1016/j.canlet.2009.10.003

Cancer Letters
Volume 291, Issue 1 , Pages 76-82 , 1 May 2010

Article Tools

* Image Usage & Resolution